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Summary The efficacy and safety of gemcitabine at a starting dose of 800 mg m2 administered once a week
for 3 weeks with 1 week's rest was investigated in chemonaive patients with advanced and/or metastatic
pancreatic cancer. Of 34 patients, 32 were evaluable for efficacy, 20 patients had metastatic stage IV disease, 25
had a performance status of I and 26 (76%) patients has significant pain on presentation. All responses were
independently validated by an external oncology review board: two patients achieved a partial response that
lasted 5.8 and 5.2 months (6.3%) and six patients were stable for at least 4 weeks. The median duration of
survival for evaluable patients was 6.3 months (range 1.6-19.2 months). The tumour markers, CEA, CA 19-9
and CA 195 were serially measured in 16 patients. There was a good correlation with tumour response when
all three markers were significantly decreased. In 4 of 16 patients, tumour marker levels decreased by > 60%,
including the two responders, one patient who survived for 12 months and one patient who showed objective
tumour shrinkage but was deemed ineligible for response evaluation because the disease was considered not to
be bidimensionally measurable. Symptomatic benefits included improvement in performance status (17.2%),
analgesic requirement (7.4%), pain score (28.6%) and nausea (27.3%). The mean number of cycles
administered was 2.5 and the mean dosage received was 890 mg m2 per injection. Seventy-four per cent of dose
administrations were given on schedule. Toxicity, particularly haematological toxicity, reported as the max-
imum WHO grade experienced by patients was mild. Infective episodes were rare and limited to WHO grade 2
(6.7%). Nausea and vomitimg was generally modest (WHO grade 3, 26.7%). Other side-effects included mild
transient flu-like symptoms (seven patients) and peripheral oedema (three patients), which was not associated
with abnormal cardiac hepatic or renal function. Gemcitabine has modest activity in pancreatic cancer, a
limited positive improvement on a range of patient benefit parameters and has a mild toxicity profile. For
these reasons and because of its novel mode of action, gemcitabine warrants further investigation in
combination studies in pancreatic cancer.
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Patients with pancreatic cancer have an extremely poor prog-
nosis, most patients presenting with obvious metastases or
unresectable locally advanced disease. In the European
Union, 60% of patients with pancreatic cancer are aged > 65
years (Jensen et al., 1990). Patients are often debilitated as a
result of the tumour and concomitant illnesses.
Chemotherapeutic regimens commonly include 5-FU (5
fluorouracil). As a single agent, 5-FU quoted response rates
are 7-30% (Brennan et al., 1993), with little additional
response in combination therapy and complete responses
being extremely rare and with no impact on survival. In
phase II trials, the median survival of patients with metas-
tatic pancreatic cancer is reported to be 12-14 weeks (Bren-
nan et al., 1993). Many other agents have been used in this
disease but as yet there is no standard chemotherapy
regimen, leaving an urgent need for the identification of new
active agents. It is difficult to assess treatment activity against
pancreatic cancer using standard radiological techniques, and
it is worthwhile using other criteria to assess objective res-
ponse (tumour markers) and symptomatic status (perfor-
mance and pain scores).
Gemcitabine (2,2-difluorodeoxycytidine, dFdC) is a novel
nucleoside analogue, with activity reported in a variety of
solid tumours. Within the cell, the parent prodrug is con-
verted into phosphorylated metabolites, which are cytotoxic:
(1) gemcitabine disphosphate (dFdCDP) inhibits ribonu-
cleotide reductase, the principal enzyme in the formation of
deoxynucleotide triphosphates for normal DNA synthesis; (2)
gemcitabine triphosphate (dFdCTP) competes with
endogenous deoxycytidine triphosphate for incorporation
into DNA. Once gemcitabine triphosphate is incorporated
into DNA, one more nucleotide is allowed to pair before the
DNA replication is terminated. By this process, termed
'masked-chain termination', the DNA chain is less easily
repaired by proofreading exonuclease enzymes (Huang et al.,
1991). Also of importance is that there are at least three
mechanisms by which gemcitabine 'self-potentiates' its
activity: (1) gemcitabine disphosphate indirectly reduces the
inhibition of the rate-limiting enzyme (deoxycytidine kinase),
which converts gemcitabine into the active triphosphate
(Plunkett et al., 1989); (2) gemcitabine disphosphate also
indirectly inhibits the principal enzyme (dCMP deaminase)
involved in the cellular clearance of gemcitabine (Xu et al.,
1992); (3) gemcitabine triphosphate directly inhibits activa-
tion of dCMP deaminase (Heinemann et al., 1988). This may
explain why, compared with ara-C, gemcitabine within
tumour cells is seen at higher levels and for longer periods
(Hertel et al., 1990), and has much greater and broader
activity in a panel of murine and human solid tumour models
(Hertel et al., 1990).
Gemcitabine has proven efficacy in phase II trials of a
number of solid tumours. These tumours include non-small-
cell lung cancer (Shepherd et al., 1993; Abratt et al., 1994;
Anderson et al., 1994), advanced previously treated epithelial
ovarian cancer (Lund et al., 1994), advanced breast cancer
(Carmichael et al., 1993), and small-cell lung cancer (Cormier
et al., 1994). In a phase II study conducted with a similar
regimen, gemcitabine produced a.response rate of 11% in
patients with advanced pancreatic cancer (Casper et al.,
1994).
This single-agent phase II study was designed (1) to deter-
mine the objective response rate to single-agent gemcitabine
given weekly for 3 weeks followed by 1 week of rest (one
cycle) to chemonaive patients with locally advanced and/or
metastatic pancreatic cancer; (2) to characterise further the
nature of the toxicity of gemcitabine in a large group of
patients with pancreatic cancer.
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Materials and methods
Study design
In this open-label, single-arm study, gemcitabine was to be
evaluated in up to 35 chemonaive patients with locally
advanced and/or metastatic pancreatic cancer. This study
was conducted jointly between the ICRF Clinical Oncology
Unit, Oxford, UK, the Technical University Munich, Ger-
many, and the Middlesex Hospital, London, UK. The
guidelines for good clinical research practice were followed.
Patients gave informed consent before entering the study,
which was approved by local ethical committees. Gem-
citabine was administered on an outpatient basis int-
ravenously once a week for 3 weeks, followed by a 1 week
rest period, this constituting one cycle of treatment. Multiple
consecutive cycles were administered and patients remained
on study until disease progression or until it was no longer in
the patient's best interest to continue. Early stopping rules
were provided to allow for study discontinuation in the event
of lack of efficacy. Sufficient responses (greater than 1 in 15
patients) were required to trigger the second phase of enrol-
ment. This procedure tested the null hypothesis (Ho) that the
true response was < 10% vs the alternative hypothesis (HA)
that the true response rate was > 30%. The significance level
(i.e. the probability of rejecting the Ho when true) was 0.063.
The power (i.e. the probability of rejecting the HO when the
alternative hypothesis was true) was 0.929.
Patients were entered into the study if they satisfied the
following inclusion criteria: histologically or cytologically
confirmed advanced or metastatic bidimensionally
measurable pancreatic cancer not amenable to curative
radiotherapy or surgery; no prior chemotherapy or
radiotherapy; performance status 0-2 (WHO Zubrod Scale);
age 18-75 years; adequate bone marrow and biochemical
parameters: white blood cell count ) 4 x I0 1', platelets
> 100 x I0 'I-, haemoglobin > 10 g dl-'; serum creatinine
. 150 mmol 1'; serum bilirubin <2 x normal; aspartate
transaminase (AST, SGOT) and alanine transaminase (ALT,
SGPT) < 3 x normal, prothrombin and partial thromboplas-
tin time < 1.5 x normal.
A starting dose of 800 mg m-2 was chosen based on phase
I data (Abbruzzese et al., 1991). However, these phase I
patients had been heavily pretreated, and it became apparent
that a higher dose of gemcitabine could be tolerated in
chemonaive patients. Therefore, the starting dose was in-
creased to 1000 mg m-2 from the sixth patient onwards.
Patients completing one cycle of therapy could have their
subsequent dose increased by up to 20%, provided there had
been no significant changes in haematological or non-
haematological parameters. Dose modification was based on
blood cell counts before injections. The dose was reduced by
50% for grade 2 haematological toxicity and omitted for
grade 3 toxicity or greater.
Efficacy was assessed by the following: full medical history
and physical examination; evaluation of WHO Zubrod per-
formance status (physician assessed); tumour measurement
by appropriate radiological tests; chest radiograph; and
evaluation of analgesic consumption for pain using the fol-
lowing six point scale: 0, none; 1, aspirin, paracetamol, non-
steroidal anti-inflammatory drugs (NSAID); 2, codeine,
dextropropoxyphene, pentazocine, buprenorphine; 3, mor-
phine sulphate, methadone, pethidine; 4, parenteral opiates;
5, neurosurgical procedures. When combinations of analgesics
were used, the highest score was adopted.
In 16 patients serial measurements of serum CEA, CA 19-9
and CA 19-5 were recorded on the first day of each cycle
before gemcitabine therapy.
Each investigator-determined response was evaluated by an
external oncology review board (ORB), which reviewed the
clinical history, signs, symptoms and appropriate radiological
tests. Evaluations were conducted using established WHO
criteria for response (World Health Organization, 1979).
Safety was evaluated at baseline and during therapy using
WHO criteria. Parameters included: full blood count; blood
chemistries (creatinine, urea, bilirubin, alkaline phosphatase,
gamma glutamyl transpeptidase, AST, ALT, lactate dehydro-
genase, glucose, electrolytes, calcium, total protein, albumin,
and uric acid); urinalysis; temperature; electrocardiogram
(ECG); vital signs (blood pressure and pulse rate); creatinine
clearance; echocardiography (for patients with a history of
cardiac disease or hypertension).
The efficacy data are reported for evaluable patients
(defined as those patients qualified in the protocol who had
completed at least one cycle of therapy). Survival was
measured from the date of the first administration of gem-
citabine to the time of death. Safety data are reported for all
enrolled patients who received at least one dose of gem-
citabine.
Results
Patient disposition
Only two patients failed to qualify according to the protocol,
one owing to lack of bi-dimensional lesions on entry into the
study and one owing to insufficient therapy (this patient was
enrolled onto the study but did not receive any gemcitabine).
Table I summarises the patient characteristics for all 34
enrolled patients. At study entry, 20 patients (60.6%) had
metastatic disease (stage IV). The liver accounted for the
largest incidence (55.9%) of metastatic involvement. Twenty-
five patients had a performance status of 1; the majority of
Table I Patient characteristics
Variable
Enrolled patients
Sex
Female
Male
Age
Mean
Median
Range
Histological differentiation of tumour
Poor
Moderate
Well
Unknown
Unspecifieda
Stage of disease
Stage II
Stage III
Stage IV
Unspecifieda
Performance status
0
1
2
Unspecifieda
Level of analgesia
0
l
2
3
4
S
Unspecifieda
Site of metastatic disease
Ascites
Bone
Liver
Lung
Lymph node
Peritoneum
Time from diagnosis to enrolment in months
Median
Range
Number (%)
34
12 (35.3)
22 (64.7)
56.0
56.0
39-72
17 (51.5)
8 (24.2)
2 (6.1)
6 (18.2)
1
3 (9.1)
10 (30.3)
20 (60.6)
1
4 (11.8)
25 (73.5)
4 (11.8)
1 (2.9)
5 (15.2)
2 (6.1)
14 (42.4)
1 (33.3)
0
1 (3.0)
l
3 (8.8)
1 (2.9)
19 (55.9)
2 (5.9)
12 (35.3)
3 (8.8)
1.4
0-9.7
aData refer to patient who was enrolled onto study but did not
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patients had a level 2 (42.4%) or level 3 (33.3%) analgesic
requirement.
Two evaluable patients (6.3%) had received prior hor-
monal therapy, 16 (50%) of the 32 evaluable patients had
received previous surgery (biopsy alone in 21.9% or palliative
procedures in 31.3%). No patients had received prior
radiotherapy or chemotherapy. Metoclopramide was the
most frequently prescribed concomitant medication (19
patients, 59.4%) and analgesics were also taken frequently.
Of 34 patients enrolled, 20 patients discontinued therapy
because of lack of efficacy. In addition, two patients on
treatment suffered an early death as a result of disease pro-
gression and three patients discontinued treatment because of
adverse events, two possibly drug related (one patient with
leucopenia (no sepsis) and one patient with throm-
bocytopenia, but no clinically significant bleeding).
Summary ofdose administrations
A total of 74% of dose administrations were given on
schedule, 4% were omitted and 14% reduced. The most
common reason for dose reduction was leucopenia (65%)
followed by thrombocytopenia (24%). Neither of these events
showed a cumulative tendency. This suggests that gem-
citabine was well tolerated (Figure 1). The mean number of
completed cycles administered was 2.5 and the mean dosage
delivered was 890mgm-2 per injection.
Primary efficacy
Of the 32 evaluable patients, two (6.3%) achieved a partial
response, six patients (18.8%) demonstrated stable disease for
at least 4 weeks, while 19 (59.4%) patients experienced
disease progression early in the study. All responses were
assessed and validated by an independent external ORB. The
first responding patient had advanced metastatic disease at
entry with moderately differentiated pancreatic adenocar-
cinoma. Lesions were confirmed in the pancreas [ultrasound
and computerised tomography (CT) scan] and in liver (CT
scan). The second responding patient entered with a diag-
nosis of locally advanced pancreatic adenocarcinoma
(confirmed by CT scan) with a poorly differentiated his-
tology. Both responding patients were entered at a starting
dose of 1000 mg m-2. Using WHO criteria of response the
duration of response for the two partial responders was 5.8
and 5.2 months. The median duration of survival for
Figure 1 Summary of dose administrations, all cycles.
evaluable patients was 6.3 months (range 1.6-19.2 months,
censored observations). Data for three tumour markers,
CEA, CA 19-9 and CA 195 were collected prospectively in 16
patients (Table II). All three tumour markers were
significantly decreased (>60%) in 4 of these 16 patients,
including both partial responders. There were two other
patients in whom all three markers decreased >60%, one
patient survived 12 months, and one patient showed objective
tumour shrinkage but was deemed ineligible for response
evaluation because the disease was considered not to be
bidimensionally measurable by the external ORB. In the
stable disease group, four patients showed a decrease of at
least 50% in one or more markers. Although there were
some minor decreases in the markers of the progressive
disease group, four patients showed a decrease of at least
50% in one or more markers.
Secondary efficacy measures
Data was collected prospectively for parameters that may
have reflected symptomatic patient benefit. Only patients
whose baseline score allowed room for improvement were
defined as eligible, thus a patient with a performance status
of 0 did not have the potential to improve, was not eligible
and was not included in the denominator. Five out of 29
(17.2%) eligible patients experienced an improvement in per-
formance status for at least 4 weeks during the study period.
The two responders both reduced their analgesic require-
ment. The first responder had an analgesic consumption
score of 2 (pretherapy and during months 1-3) which drop-
ped to 0 (during months 4-6). The second responder had an
analgesic consumption score of 3 (pretherapy and during
months 1 -3), then 0 (during month 4), then 2 (during
months 5 and 6). There were improvements in pain score
(eight patients out of 28, 28.6%) and nausea (three patients
out of 11, 27.3%). The median durations of improvement
were: performance status, 7 weeks; analgesic consumption,
10.9 weeks; pain, 9.3 weeks; nausea, 12.0 weeks.
Toxicity profile
Laboratory and symptomatic toxicities were assessed using
WHO grades. The WHO grades are not reported on a per
Table II Maximum percentage change in CEA, CA 19-9 and CA
195 tumour markersa and response status patients in whom all three
markers were obtained (n = 16)
Patient number CEA CA 19-9 CA 195
Partial response
22 -94.3 -98.5 -98.7
23 -92.3 -86.4 - 88.2
Non-evaluable
13b -87.7 -77.6 -62.8
9 68.2 - 76.9 75.7
Stable disease
4c - 77.4 -90.2 -93.5
6 - 52.4 - 18.8 44.4
28 20.0 -21.1 24.3
29 38.0 -93.8 -94.0
31 - 55.6 -42.9 - 50.0
Progressive disease
3 -25.0 -48.3 - 39.7
14 1150.0 -41.3 308.6
25 37.1 11.8 34.00
26 200.0 233.3 650.0
27 250.0 - 20.0 27.1
30 119.4 161.5 254.4
32 - 29.2 -40.0 -40.0
aNumbers shown relate to a percentage change over baseline,
decrease being shown by minus and increase being shown by plus.
bPatient who showed objective tumour shrinkage but was deemed
ineligible for response because the disease was considered not to be
bidimensionally measurable by the external oncology board. cPatient
with stable disease with unusually long duration of survival, 12
months.
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injection basis, but represent the worst grades experienced by
patients during the whole study period (Figures 2-4).
Haematological toxicity was mild (Figure 2). WHO grade 3
and 4 leucopenia was 6.1 and 0% and one patient was
discontinued owing to a grade 3 leucocyte toxicity in the
absence of infection. The incidence of infection associated
with this level of leucopenia was low (6.7% patients at grade
2). WHO grade 3 and 4 neutropenia was 18.2 and 6.3%.
There was no WHO grade 4 anaemia, with grade 3 toxicity
in one patient and only four patients requiring blood trans-
fusions. WHO grade 3 and 4 platelet toxicity was 6.1 and
3.0%, which resulted in discontinuation for one patient and a
platelet transfusion for one patient who was asymptomatic.
Liver and renal toxicity were rare and when present were
mild and transient (Figures 3 and 4). There was no evidence
of non-reversible cumulative organ toxicity.
No WHO grade 4 toxicities were reported for any of the
16 symptomatic parameters assessed (Table III). WHO grade
3 toxicity was reported only for nausea and vomiting
(26.7%), diarrhoea (3.3%) and pain (3.3%).
Other symptomatic toxicities, not WHO graded, were
classified as mild, moderate or severe. Nine patients
experienced lethargy, some presumed to be drug-related and
some as a result of underlying disease, but it is difficult to
separate these causes. Flu-like symptoms were experienced in
seven patients and peripheral oedema in three patients, which
was not associated with abnormal cardiac, hepatic or renal
function.
Discussion
The initial gemcitabine dosing schedule of 800 mgm-2 was
increased to 1000 mg m-2 after the fourth patient enrolled, as
a result of the low toxicity experienced in this study and also
in other phase II studies with previously untreated patients.
Two patients (6.3%) had partial responses of at least 4 weeks
duration. These responses were confirmed by an external
ORB. In both responders all three tumour markers (CEA,
CA19-9, CA195) were significantly decreased. There were two
other patients in whom all three markers significantly
decreased, one patient with a duration of survival of 12
months, which is unusual in a patient with advanced panc-
reatic cancer, and one patient with objective tumour shrin-
kage but whose disease was judged not to be bidimensionally
measurable and was deemed ineligible for response evalua-
tion. These data show a good correlation with objective
tumour response when all three markers are considered. It
would be interesting to conduct further studies looking at
this relationship between these three markers and tumour
response.
A proportion of patients benefited from improvements in a
number of secondary efficacy and disease-related symptom
parameters, such as performance status (17.2%), analgesic
requirement (7.4%), pain score (28.6%) and nausea (27.3%).
The median durations of improvement were 7, 10.9, 9.3 and
12 weeks respectively.
Gemcitabine was well tolerated and WHO grade 3 and 4
toxicity was infrequent. Haematological toxicity was partic-
ularly modest. There was no WHO grade 3 or 4 infection,
which reflected the low level and duration of myelosuppres-
sion. Transient elevations of hepatic enzymes were commonly
reported but were mild and of no apparent clinical relevance.
There was no WHO grade 3 or 4 alopecia. Pancreatic cancer
patients would be expected occasionally to experience nausea
and vomiting and WHO grade 3 nausea and vomiting was
experienced in only 26.7% of patients with no grade 4 tox-
icity.
In an earlier study with gemcitabine in the same schedule
but with a starting dose of 800 mgm-2, a response rate of
11% has been reported (Casper et al., 1994). In both panc-
reatic cancer studies, the response rates with gemcitabine
have been independently validated by an external ORB, and
still compare well with response rates reported in other
studies that were not independently validated. No single
0-
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Table III Summary of symptomatic toxicity by WHO grade
(percentage of patients, n = 33)
Toxicity parameters 2 3 4
Cutaneous 10.0 0 0
Fever 20.0 0 0
Hair 0 0 0
Infection 6.7 0 0
Nausea/vomiting 20.0 26.7 0
Pulmonary 0 0 0
State of consciousness 13.3 3.3 0Gemcitabine in advanced pancreatic cancer
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agent has been shown to be superior to 5-FU alone in terms
of palliation or survival benefit yet the response rates with
5-FU remain low in prospective randomised trials: 16% (6 of
32 patients), 30% (three of ten patients), and 7% (1 of 14
patients) (Brennan et al., 1993). The overall response rate
with ifosfamide, an agent increasingly used in pancreatic
cancer is still only 10% (Brennan et al., 1993). Combination
therapy has not offered significant symptomatic or survival
benefit, and its use outside clinical trials is not recommended
because of greater toxicity.
The median overall survival of 6.3 months (censored obser-
vations, surviving patients still in follow-up) compares well
with a median survival of 12-14 weeks for patients with
metastatic pancreatic cancer included in phase II studies
(Brennan et al., 1993).
Pancreatic cancer presents special difficulties, both in the
objective measurement of tumour size and in assessing the
degree of patient benefit afforded by any tumour shrinkage.
In patients with pancreatic cancer it is often difficult to
obtain accurate tumour measurements because of the loca-
tion of the pancreas in the retroperitoneum and the difficulty
in distinguishing tumour from normal pancreas on CT.
Determination of objective response is therefore difficult and
unreliable in most patients. This may explain the widely
varying response rates reported in pancreatic cancer for the
same agents. Whereas for most cancers tumour-related symp-
toms are closely related to tumour bulk, as a result of the
location of the tumour in pancreatic cancer even small reduc-
tions in tumour size may result in significant clinical benefit
in some patients. In the treatment of metastatic pancreatic
cancer therapeutic options are limited and improvement in
quality of life therefore assumes a high priority. The
beneficial effects of gemcitabine on these secondary measures
were somewhat less than in the study by Casper et al. (1994)
but are nevertheless promising. The suggestion of improve-
rovements in pain score, analgesia requirement and perfor-
mance status are encouraging. Furthermore, gemcitabine has
shown remarkably little haematological, liver, renal or symp-
tomatic toxicity.
In conclusion, in this study the independently validated
response rate to gemcitabine in patients with advanced/
metastatic pancreatic cancer was 6.3%. This compares with
the 11% reported by Casper et al. (1994) and is equivalent to
the activity of 5-FU as a single agent or in combination.
Although this level of objective tumour response can at best
be described as modest, symptomatic benefit was reported for
patients on the study. Recently a prospective randomised
trial was performed in pancreatic cancer patients to evaluate
symptom improvement (pain) and Karnofsky performance
status according to strict criteria (Moore et al., 1995). In this
trial of 126 patients randomised to gemcitabine 1000 mg m-2
vs weekly 5-FU 600 mg m-2, significantly more patients
(P = 0.0022) derived clinical benefit in the gemcitabine
(23.8%) vs the 5-FU group (4.8%). Median survival was also
significantly (P = 0.0025) higher, with 24% of gemcitabine
patients treated with gemcitabine and 6% of 5-FU patients
alive at 9 months. These data are also supported by a
single-arm 63 patient study, which showed that 27% of 5-FU
refractory patients treated with gemcitabine derived clinical
benefit (Rothenberg et al., 1995). These data on tumour
response, symptom benefit and survival, taken together with
its modest toxicity and novel mechanism of action, suggest
that gemcitabine warrants further clinical investigation both
as a single agent evaluating other schedules and in combina-
tion with other agents such as modulated 5-FU.
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